Item 7.01 Regulation FD Disclosure.
Attached is the updated investor presentation of
Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company.
These forward-looking statements are identified by the use of words such as
"will," "develop," "project," "expect," and "expand," among others.
Forward-looking statements in this report are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual results
to vary, including such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or approvals,
clinical results may not be replicated in actual patient settings, protection
offered by the Company's patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available market for the
Company's products will not be as large as expected, the Company's products will
not be able to penetrate one or more targeted markets, revenues will not be
sufficient to meet the Company's cash needs, fund further development, as well
as uncertainties relative to the COVID-19 pandemic and economic development,
varying product formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other risks detailed
from time to time in the Company's filings with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Number Description 99.1 Investor Presentation as ofMay 10, 2023 . 104 Cover Page Interactive Data File (formatted in inline XBRL in Exhibit 101). 2
© Edgar Online, source